Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evacetrapib Warfarin Interaction Study
NCT02161731Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of evacetrapib in hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of S-Warfarin at Day 17 and Maximum Observed Concentration (Cmax) of S-warfarin at Day 17. Started Jun 2014; status: completed.
02
Drugs
evacetrapib
03
Conditions
hypercholesterolemiaatherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT02161731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161731.